DOCSLIB.ORG

Ol'sin('HE Related U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ol'sin('HE Related U.S llIIlIlllIlIlIllIlIllIllIllIIIIIIIIIIIIIIIIIIIIllIllllIIlIllllllIIIlllIlIllIIIIIIIIIIIIIII US 20140275135A1 (») United States (12) Patent Application Publication (io) Pub. No.: US 2014/0275135 A1 GENOV et al. (43) Pub. Date: Sep. 18, 2014 (54) SAI.TS AND SOI.ID IJORVIS Olr (22) liiled: Msr. 13, 2014 ISOQUI Ij OLINONES AND COMPOSITION Ol'SIN('HE Related U.S. Application Data COMPRISIN(1 A'vD VIETIIODS SAME (60) Provisional application No. 61/789,740, lilcd on Mar. 15. 2013. (71) Applicant: Infinity Pharmaceuticals, Inc., Publication ('lsssilicstisn ('anibridge, MA (US) (51) Int. CL (72) Inventors Daniel G. GENOV, Boston. MA (US). Ct)7D 401//4 (2006.01) Louis GRENIER, Newton. )vLA (US). G/11N 31/16 (2006 01) Andrew u. IIA(IUI'., ( helmsford. MA (52) U.S. «L (J.JS); Alcsandcr Redvers 1(BERI.IN, CPC ............ Cd 7D 401//4 GP/Ãdh'168 ('anibridge (2013.01)1 ((iu); I.udouc Sylvsin (2013.01) Merc RENOU. Cambridge ((iB); 514/275: 544/324; 436/42 Susana DEL RIO GANCEDO, IJSV('......... Ctunbridgc (GB) (5 7) ABSTRACT Sohd fonus of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, phar- (73) Assigncc. Infinity Pharmaceuticslt, Inc., maceutical compositions, mid methods of treatment of dis- Ctunbridgc, MA ((JS) eases md conditions associated with kinase activity. includ- uig PL3 kinasc acuvity. arc descnbed hcrmn. Also providtxl hcrmn arc proccsscs for prcpanng compounds, solid fonna (21) Appl. No . 14/209,842 thereof, turd phannaccutwsl compositions thereof Patent Application Publication Sep. 18, 2014 Sheet 1 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 2 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 3 of 54 US 2014/0275135 A1 95 90 85 80 75 /0 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340'C FIG. 2A 1TA, 9.1880m9 Step -2.7575!, 100 -" '5'4m 95 =- 90= 85-. 25.9657K 2.385/mg 80~ 75 70 "I "I ' 9 . 9 7: 7 40 Ki 80 100 120 140 160 180 2i30 220~240 260 280 300 320 340'C FIG. 2B 04 12Ã00mo 40 60 80 100 120 140 160 180 200 220 240 260 280 'C FIG. 2C Patent Application Publication Sep. 18, 2014 Sheet 4 of 54 US 2014/027i135 A1 Wg -1 40 60 80 100 120 140 160 180 200 220 240 260 280 800 „20 340 C FIG. 3A Wq -1 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340'C FIG. 3B letegrel - 24.41mJ - novelized -12,67Jg I 0neet 21 8.42 'C Wg -1 0.0 40 60 80 100 120 140 160 180 200 220 240 260 280 *C FIG. 3C Patent Application Publication Sep. 18, 2014 Sheet 5 of 54 US 2014/0275135 A1 0. /0 0,60 E Ã 0. 50 ~ 0.40 4 0.30 Patent Application Publication Sep. 18, 2014 Sheet 6 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 7 of 54 US 2014/027i135 A1 C C R E CD CCt CG 1 ! ! 1 T ! ! l ! ! lm CD CO (2& ~ ~ M CO CD ~ ~ C3 CG eX& LC) CFl CB CA CC CC CF& QO CO CQ CQ CO j 0$ Patent Application Publication Sep. 18, 2014 Sheet 8 of 54 US 2014/027i135 A1 Form 1 .'=orrn 1A After 24 hours standing Li ~ Form 1A After filtration 'l0 20 2 —Theta — Scale Patent Application Publication Sep. 18, 2014 Sheet 9 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 10 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 11 of 54 US 2014/027i135 A1 C CN j i/3 p ~ C:i 93 t3 c& E lo o cudQ K V Patent Application Publication Sep. 18, 2014 Sheet 12 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 13 of 54 US 2014/027i135 A1 300 5 10 l5 20 25 30 35 40 8 -28Ideg) Patent Application Publication Sep. 18, 2014 Sheet 14 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 15 of 54 US 2014/0275135 A1 Patent Application Publication Sep. 18, 2014 Sheet 16 of 54 US 2014/027i135 A1 o ! ~ 8 8 8 8 g 8 8 8 8 ssmmwsIIIQN8IQQ88$8$88~ (""ivf103)v!) (SlLao0)93 Patent Application Publication Sep. 18, 2014 Sheet 17 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 18 of 54 US 2014/0278135 A1 ";0)iep -0.89? 4Ã CA 3,!930ma -29. 3883e-03ma 1GG Siep -12.48! &Xp -0.4110mg Siep 6.449'i8) 0.2'24mg 80 ~- -r 40 60 80 100 120 140 160 180 200 220 240 260 280 300 220 340'0 FIG. 13A S)ep -1.0667'1) ! 63) 'ace CA 81 -65 88PPe- 8.8046/ 90~ .!a Sma 85~ 80 -„! 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 0 FIG. 138 Step -0.6189!. lCA 11,2966)mg — 69.997, e — 03!ai] ', 00 g)" ~ Step -14 6637/ -1.6481mg 90 -„ 85-1 40 60 80 100 120 140 160 180 200 220 240 260 280 '0 FIG. 13C Patent Application Publication Sep. 18, 2014 Sheet 19 of 54 US 2014/027i135 A1 Wg -1 2,0 0 0',0 -0" 40 60 80 100 120 140 160 180 200 22G 240 260 280 300 220 340'"C FIG. 34A 40 60 80 100 12G 140 160 180 20G 220 240 260 280 00 32G 340'C FIG. 34B Wg -1; 0 09C'6200rlg -1- 2~ 'C 0 i.-e: 1 9 l.99 ~er'9 196 66'",. 40 6G 80 100 120 140 160 180 00 220 240 260 280 'C FIG. 14C Patent Application Publication Sep. 18, 2014 Sheet 20 of 54 US 2014/027i135 A1 0.60 ~ 0.40 E 5 0X 0.25 ~ 0,20 0.15 0 !0 20 30 40 50 60 70 80 90 x-RH(x) FIG. 15 Patent Application Publication Sep. 18, 2014 Sheet 21 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 22 of 54 US 2014/027i135 A1 1 Patent Application Publication Sep. 18, 2014 Sheet 23 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 24 of 54 US 2014/027i135 A1 cD co c) I cD CD cD CD CD cD cD CD cD cD '') C' ) Patent Application Publication Sep. 18, 2014 Sheet 25 of 54 US 2014/0275135 A1 Step -7./6?5,"r,. -0.393." Ii9 Step -9.9'i 842 -0.5'-2') — — — — — — — r r r 1--r r r r-T r" r r r i r,, ] ] T 9 7 ] g I 1 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340"C FIG. 18A 40 60 80 100 120 140 160 180 200 ?20 '?40 260 280 300 320 340'&: FIG. 38B Patent Application Publication Sep. 18, 2014 Sheet 26 of 54 US 2014/027i135 A1 Wq -1 0.0 OSC ! 40„"Oreg btagra[ -43.34mJ — 0.4- ( aorraa[iz.d -3[296.:g -1 -06 ([, a 7 I .-"'aak [85.':.! 'C -1. 1 -1.2 -1A -r--"--r-- --v--r -T'--[-- r--f--&--T- T- 7--i-- --i--T - --T -r--[-- — T--t"- [--r--[--'- - i-- ["- T 40 60 80 100 120 140 160 180 20G 220 240 260 280 300 320 340 C FIG. 39A 1[/g --1 1,0 0.6 0.4 0.2 0.0 -0.2 40 60 80 100 12Q 140 160 180 200 220 240 260 280 300 320 340"C FIG. 19B Patent Application Publication Sep. 18, 2014 Sheet 27 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 28 of 54 US 2014/027i135 A1 (DCJEDCD&C)NCJN\DcD(-JCJED'.DER3 ]"T''T', 'T$ 'I (-JCIC)&D(- at ( I;t, T T T T i i 7 7TT, ar n&awaanac~nnac acianamnaconHC'BMOOf (SDIIJw"MM CVMCOI CGi'3M WC% C lMCM (0/UllOJ) Ul ] Patent Application Publication Sep. 18, 2014 Sheet 29 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 30 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 31 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 32 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 33 of 54 US 2014/027i135 A1 a a C! c «L «D F I«l canQ c c) CCl 4C ) ID «W «& V I ID «D I: I n- Patent Application Publication Sep. 18, 2014 Sheet 34 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 35 of 54 US 2014/0275135 A1 Patent Application Publication Sep. 18, 2014 Sheet 36 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 37 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 38 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 39 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 40 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 41 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 42 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 43 of 54 US 2014/027i135 A1 Patent Application Publication Sep. 18, 2014 Sheet 44 of 54 US 2014/027i135 A1 so'vent Posed in poiyrnonph ee(een IP.I I I THT 1-II!eTHI I80E iL 4eT 20 2 —Theta — Scoie FllG.
Load more

Recommended publications
  • WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 A 61K 35/1 7 (20 15.0 1) A 61P 35/00 (2006 .0 1) Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US). (21) International Application Number: (72) Inventor: ALBERTSON, Tina; 400 Dexter Ave. N., Suite PCT/US2018/035755 1200, Seattle, WA 98109 (US). (22) International Filing Date: (74) Agent: AHN, Sejin et al; Morrison & Foerster LLP, 1253 1 0 1 June 2018 (01 .06.2018) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 14,774 02 June 2017 (02.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/5 15,530 05 June 2017 (05.06.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/521,366 16 June 2017 (16.06.2017) u s HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/527,000 29 June 2017 (29.06.2017) u s KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/549,938 24 August 2017 (24.08.2017) u s MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/580,425 0 1 November 2017 (01 .11.2017) u s OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/593,871 0 1 December 2017 (01 .12.2017) u s SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/596,764 08 December 2017 (08.12.2017) u s TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Physiologically Based Pharmacokinetic Modeling in Regulatory Decision‐Making at the European Medicines Agency
    ARTICLES Physiologically Based Pharmacokinetic Modeling in Regulatory Decision-Making at the European Medicines Agency E Luzon1, K Blake1, S Cole2,3,4, A Nordmark4,5, C Versantvoort3,6 and E Gil Berglund3,5 Physiologically based pharmacokinetic (PBPK) modeling is a valuable tool in drug development and regulatory assessment, as it offers the opportunity to simulate the pharmacokinetics of a compound, with a mechanistic understanding, in a variety of populations and situations. This work reviews the use and impact of such modeling in selected regulatory procedures submitted to the European Medicines Agency (EMA) before the end of 2015, together with its subsequent reflection in public documents relating to the assessment of these procedures. It is apparent that the reference to PBPK modeling in regulatory public documents underrepresents its use. A positive trend over time of the number of PBPK models submitted is shown, and in a number of cases the results of these may impact the decision- making process or lead to recommendations in the product labeling. These results confirm the need for regulatory guidance in this field, which is currently under development by the EMA. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE WHAT THIS STUDY ADDS TO OUR KNOWLEDGE TOPIC? þ This is the first work presenting the situation in the Europe- þ PBPK is a cutting-edge technology that is increasingly being an Union and confirms what was detected by the FDA is a applied to drug development to address various aspects related global trend. to clinical pharmacology. Previous works by the FDA acknowl- HOW THIS MIGHT CHANGE CLINICAL PHARMA- edge its use in regulatory submissions in the US, but so far there COLOGY OR TRANSLATIONAL SCIENCE is no analysis of the European perspective.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Related Kinases (VRK) Bound to Small-Molecule Inhibitors Identifies Different P-Loop Conformations
    Structural characterization of human Vaccinia- Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations Rafael M. Couñago1,2*, Charles K. Allerston3, Pavel Savitsky3, Hatylas Azevedo4, Paulo H Godoi1,5, Carrow I. Wells6, Alessandra Mascarello4, Fernando H. de Souza Gama4, Katlin B. Massirer1,2, William J. Zuercher6, Cristiano R.W. Guimarães4 and Opher Gileadi1,3 1. Structural Genomics Consortium, Universidade Estadual de Campinas — UNICAMP, Campinas, SP, Brazil. 2. Centro de Biologia Molecular e Engenharia Genética, Universidade Estadual de Campinas, Campinas, SP, Brazil. 3. Structural Genomics Consortium and Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, UK. 4. Aché Laboratórios Farmacêuticos SA, Guarulhos, SP, Brazil. 5. Department of Biochemistry and Tissue Biology, Institute of Biology, State University of Campinas, Campinas, Brazil. 6. Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA. *Correspondence to Rafael M. Couñago: [email protected] (RMC) Supplementary information 1 SUPPLEMENTARY METHODS PKIS results analyses - hierarchical cluster analysis (HCL) A hierarchical clustering (HCL) analysis was performed to group kinases based on their inhibition patterns across the compounds. The average distance clustering method was employed, using sample tree selection and sample leaf order optimization. The distance metric used was the Pearson correlation and the HCL analysis was performed in the TmeV software 1. SUPPLEMENTARY REFERENCES 1 Saeed, A. I. et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 34, 374-378, (2003). SUPPLEMENTARY FIGURES LEGENDS Supplementary Figure S1: Hierarchical clustering analysis of PKIS data. Hierarchical clustering analysis of PKIS data.
    [Show full text]
  • Sarcoma Metabolomics: Current Horizons and Future Perspectives
    cells Review Sarcoma Metabolomics: Current Horizons and Future Perspectives Miguel Esperança-Martins 1,2,3,* , Isabel Fernandes 1,3,4 , Joaquim Soares do Brito 4,5, Daniela Macedo 6, Hugo Vasques 4,7, Teresa Serafim 2, Luís Costa 1,3,4 and Sérgio Dias 2,4 1 Centro Hospitalar Universitário Lisboa Norte, Medical Oncology Department, Hospital Santa Maria, 1649-028 Lisboa, Portugal; [email protected] (I.F.); [email protected] (L.C.) 2 Vascular Biology & Cancer Microenvironment Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; tserafi[email protected] (T.S.); [email protected] (S.D.) 3 Translational Oncobiology Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal 4 Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; [email protected] (J.S.d.B.); [email protected] (H.V.) 5 Centro Hospitalar Universitário Lisboa Norte, Orthopedics and Traumatology Department, Hospital Santa Maria, 1649-028 Lisboa, Portugal 6 Medical Oncology Department, Hospital Lusíadas Lisboa, 1500-458 Lisboa, Portugal; [email protected] 7 General Surgery Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal * Correspondence: [email protected] Abstract: The vast array of metabolic adaptations that cancer cells are capable of assuming, not Citation: Esperança-Martins, M.; only support their biosynthetic activity, but also fulfill their bioenergetic demands and keep their Fernandes, I.; Soares do Brito, J.; intracellular reduction–oxidation (redox) balance. Spotlight has recently been placed on the en- Macedo, D.; Vasques, H.; Serafim, T.; ergy metabolism reprogramming strategies employed by cancer cells to proliferate.
    [Show full text]
  • Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2012, Article ID 604204, 16 pages doi:10.1155/2012/604204 Review Article Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb Frederic Lallemand,1 Philippe Daull,1 Simon Benita,2 Ronald Buggage,1 and Jean-Sebastien Garrigue1 1 Research and Development Department, Novagali Pharma SA, 1 rue Pierre Fontaine, 91058 Evry Cedex, France 2 The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, POB 12065, 91120 Jerusalem, Israel Correspondence should be addressed to Jean-Sebastien Garrigue, [email protected] Received 7 September 2011; Accepted 9 November 2011 Academic Editor: Abhijit A. Date Copyright © 2012 Frederic Lallemand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to evaluation in clinical trials. A major challenge of the formulation work was the selection of a cationic agent with an acceptable safety profile that would ensure a sufficient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions were observed in preclinical studies to have an inherent benefit on the ocular surface.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • Withdrawal Assessment Report for Jenzyl, INN: RIDAFOROLIMUS
    3 December 2012 EMA/774827/2012 Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report for Jenzyl International non-proprietary name: Ridaforolimus Procedure no EMEA/H/C/2259 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. This withdrawal Assessment Report is based on the latest assessment report adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with the “Questions and Answers” document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 1. RECOMMENDATION Based on the CHMP review of the data and the Applicant’s response to the CHMP LOQ on quality, safety and efficacy, the CHMP considers that the application for Jenzyl, an orphan medicinal product, in the treatment metastatic soft tissue sarcoma or bone sarcoma as maintenance therapy for patients who have completed at least 4 cycles of chemotherapy without evidence of disease progression in adult and paediatric patients aged 13 through 17 years with weight over 100 pounds or 45.4 kilograms). is not approvable since "major objections" still remain, which preclude a recommendation for marketing authorisation at the present time.
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 26, No. 4, 2012 WHO Drug Information Contents International Regulatory Regulatory Action and News Harmonization New task force for antibacterial International Conference of Drug drug development 383 Regulatory Authorities 339 NIBSC: new MHRA centre 383 Quality of medicines in a globalized New Pakistan drug regulatory world: focus on active pharma- authority 384 ceutical ingredients. Pre-ICDRA EU clinical trial regulation: public meeting 352 consultation 384 Pegloticase approved for chronic tophaceous gout 385 WHO Programme on Tofacitinib: approved for rheumatoid International Drug Monitoring arthritis 385 Global challenges in medicines Rivaroxaban: extended indication safety 362 approved for blood clotting 385 Omacetaxine mepesuccinate: Safety and Efficacy Issues approved for chronic myelo- Dalfampridine: risk of seizure 371 genous leukaemia 386 Sildenafil: not for pulmonary hyper- Perampanel: approved for partial tension in children 371 onset seizures 386 Interaction: proton pump inhibitors Regorafenib: approved for colorectal and methotrexate 371 cancer 386 Fingolimod: cardiovascular Teriflunomide: approved for multiple monitoring 372 sclerosis 387 Pramipexole: risk of heart failure 372 Ocriplasmin: approved for vitreo- Lyme disease test kits: limitations 373 macular adhesion 387 Anti-androgens: hepatotoxicity 374 Florbetapir 18F: approved for Agomelatine: hepatotoxicity and neuritic plaque density imaging 387 liver failure 375 Insulin degludec: approved for Hypotonic saline in children: fatal diabetes mellitus
    [Show full text]